Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.

To systematically review existing evidence on cost-effectiveness of semaglutide versus other T2D medications.

系统回顾现有证据，比较Semaglutide与其他T2D药物的成本效益。

data_sources

PubMed, Embase, and the Cost-Effectiveness Analysis Registry (by 11 June 2024).

PubMed、Embase 和成本效益分析登记处（截至 2024 年 6 月 11 日）。

study_selection

A total of 45 articles (with 119 comparisons) from 2019 onward were included, representing Europe (n = 24), North America (n = 13), and Asia (all from China) (n = 8).

共纳入了 2019 年以来的 45 篇文章（包含 119 项比较），分别代表欧洲（n = 24）、北美（n = 13）和亚洲（全部来自中国）（n = 8）。

data_extraction

Study characteristics and model characteristics/inputs/results were extracted.

提取了研究特征以及模型特征/输入/结果。

Lifetime costs and quality-adjusted life-years were evaluated.

评估了终身成本和质量调整生命年。

Proportions for cost-effectiveness outcomes (dominant, cost-effective, not cost-effective) were calculated.

计算了成本效益结果（主导、成本效益、非成本效益）的比例。

Subgroup analyses by region, sponsor type, comparator type, and model assumptions were performed.

按地区、赞助类型、比较类型和模型假设进行了亚组分析。

In sensitivity analysis a standard willingness-to-pay threshold was applied.

在敏感性分析中应用了标准的支付意愿阈值。

data_synthesis

Of the articles included, 93.3% included adoption of a lifetime horizon and 84.4% a health care perspective and 68.9% were industry sponsored.

在纳入的文章中，93.3%采用了终身视角，84.4%采用了医疗保健视角，而68.9%得到了工业资助。

For most studies reporting quality was high (86.7%).

大多数研究报告的质量较高（86.7%）。

Overall, semaglutide was dominant/cost-effective in 73.9% of all comparisons.

总体而言，在所有比较中，73.9%的比较显示司美格鲁肽具有优势/成本效益。

Notably, semaglutide was found to be dominant/cost-effective in all comparisons sponsored by Novo Nordisk versus in 50.0% of these funded by nonindustry sponsors and in none funded by other industry sponsors.

值得注意的是，诺和诺德赞助的所有比较中发现司美格鲁肽具有优势/成本效益，而在非行业赞助的50.0%的比较中也具有优势/成本效益，在其他行业赞助的比较中则没有。

Additionally, semaglutide was more cost-effective in high-income countries and in studies with adoption of a broader perspective, longer horizon, and lower discount rates.

此外，司美格鲁肽在高收入国家以及在采用更广泛视角、更长视野和更低折扣率的研究中更具成本效益。

Results remained consistent with conversion with a common currency unit and willingness-to-pay threshold of US$50,000.

结果与使用统一货币单位和50,000美元的支付意愿阈值进行转换保持一致。

limitations

Less detailed demographic information for more granular analyses.

对于更细致的分析，人口统计信息的细节较少。

Conclusions

Semaglutide is generally cost-effective compared with other glucose-lowering medications in evaluation against within-study willingness-to-pay thresholds; however, results varied by study sponsor type, region, and model assumptions, highlighting the need for transparent and context-sensitive economic evaluations.

Semaglutide 与其他降糖药物相比，在研究中的支付意愿阈值评估中通常具有成本效益；然而，结果因研究赞助类型、地区和模型假设而异，强调了需要透明和具有情境敏感性的经济评估。